Bringing the Oncology Community Together

Dr. Peeters on KRAS/NRAS Mutations in mCRC

Marc Peeters, MD, PhD
Published Online: Thursday, February 6, 2014
Marc Peeters, MD, PhD, department of oncology, Antwerp University Hospital, Antwerpen, Belgium, discusses an analysis of RAS mutations in the phase III study 20050181, which compared panitumumab plus FOLFIRI versus FOLFIRI for second-line treatment of metastatic colorectal cancer (mCRC).

Peeters says before patients with mCRC are treated with anti-EGFR agents, they are tested for KRAS exon 2 status of their tumor. If the patient has a mutated tumor, they are not treated with anti-EGFR agents such as panitumumab or cetuximab.

In an analysis of the phase III study 20050181, researchers first looked for the wild-type patients in KRAS exon 2 and then looked at the exon 3 and exon 4 in the KRAS genes and NRAS genes, Peeters says. The analysis showed an additional 18% of new mutations outside the KRAS exon 2 gene. Further analysis showed that if a patient has a mutated tumor, there is no benefit but there is also no harm when a patient is treated with panitumumab plus FOLFIRI. If patients have a wild-type RAS tumor, the analysis showed that there is a clear benefit in progression-free survival and overall survival when panitumumab is combined with FOLFIRI, Peeters says.

Related Articles
First- and Later-line Use of Panitumumab in mCRC
Panelists describe the results of clinical trials of the EGFR inhibitor panitumumab as first-line or later-line therapy for patients with metastatic colorectal cancer and the importance of RAS testing for patient selection.
Next-Generation Targeted Therapies in NSCLC
In this segment, panelists discuss the number of early-phase clinical trials that have demonstrated impressive efficacy for next-generation ALK and EGFR inhibitors for patients with non-small cell lung cancer.
Treatment of Unresectable RAS Wild-type Metastatic CRC
Panelists discuss the frontline treatment of patients with unresectable metastatic colorectal cancer, which has become a more challenging decision in recent years as a result of studies focused on RAS mutations.
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.